AI in drug development: FDA draft guidance addresses product lifecycle, risk
Regulatory NewsJeff Craven
Artificial intelligence/machine learning (AI/ML)Biologics/ biosimilars/ vaccinesGuidancePharmaceuticalsProduct developmentProduct LifecycleRisk managementUnited StatesUS Food and Drug Administration (FDA)